Dear Colleagues,

THIS PAST YEAR HAS BEEN A VERY EXCITING ONE FOR THE HOOSIER ONCOLOGY GROUP. We have welcomed many new sites, engaged with new research partners, and have brought on several new members to our Board. You will also notice that we have a new logo! I believe the Hoosier Oncology Group has positioned itself to be the premier research organization of its kind anywhere in the country.

As we enter into 2010, I’d like to invite everyone to join us for our 25th Anniversary Gala event in April. Very few organizations make it 25 years! We can be very proud of the work we have done, but our mission is not yet complete. We remain determined to find the better cancer therapies for tomorrow.

Thank you for your support over the years and I look forward to a wonderful 2010.

Nasser Hanna, M.D.
Chairman
THIS YEAR HAS TAUGHT ME TWO THINGS, focus on people and data and we will do great things in the next 25 years just like we did in the first 25 years.

We convened in 2009 a great team of people deeply invested in the Hoosier Oncology Group’s success to review the “data” on our organization and the environment we operate in. I summarize the direction that flowed from six months of planning with our outstanding staff, founders, survivors, passionate volunteers and the next generation cancer researchers poised to inherit Hoosier Oncology and continue The Legacy of quality cancer research of the highest integrity.

1. Strengthen IU relationship to be able to deliver community outreach thru research site development, execute quick transition from academic-centered Phase 1 studies to Phase 2 community-centered studies, and facilitate physician education as the practice of oncology becomes increasingly complex.

2. Support clinical trial working groups and develop focused support of junior faculty and fellows to strengthen their research capabilities and promote career advancement thru publication of impactful research.

3. Facilitate greater engagement between community and academic research physicians and ensure a bidirectional flow of information around unmet needs and science that matters to the patient.

4. Listen to our sponsors needs and develop relationships that are mutually beneficial and seek to improve how research is conducted to ever increasing standards of quality, speed, and value.

All relationships in the network have been strengthened. Hoosier Oncology is only as strong as its network, and we have added strands operationally with all major stakeholders:

Patients thru community patient advocacy programs and integrating advocates into protocol and consent review, and ultimately in better dissemination of study results. Keeping the patient at the center of our operations elevates our ability to meet the right cancer challenges.

Community sites thru adoption of clear performance standards, well-funded studies, and higher visibility within CTWG’s and board representation. Community engagement makes the mission run.
Translational Researchers thru ongoing relationship building with Purdue and IU lab scientists and clinicians as evidenced in the Walther Cancer Foundation Biorepository Sample Collection Study. Personalized treatment is one step closer with these efforts.

Dedicated Volunteer ranks from Board to Research Advocacy thru a revitalization plan to diversify and expand our organizational leadership skills and community footprint. Meeting a mission as complex as conducting cancer research in a network of academic and community sites requires input from survivors, business leaders, community representatives in addition to outstanding oncologists.

Drug Company Sponsors thru more transparency in project start-up to publication that includes better qualifying of sites for opening, enhanced budgeting, and consistent and relevant communications on study performance, early identification of potential issues, and urgency in problem resolution. Curing cancer is too complex a mission to not have high touch relationships with your partners.

Our Employees thru clear performance expectations, supported development, and promotion of a culture that engages all of our network of stakeholders and actively pursues best practices. Internal metrics are trending up, from employee satisfaction to the bottom-line.

We are anxious to defeat cancer. Victory by victory, Hoosier Oncology will continue leading cancer research, close to home.

Sincerely,

Peter “Quake” Pletcher
Executive Director
Hoosier Oncology Foundation, Inc.

Nasser Hanna, M.D., Chairman, Associate Professor at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Vice-Chair, Principal Investigator for the Northern Indiana Cancer Research Consortium, South Bend, IN

James Ruckle, Ph.D., Secretary/Treasurer, President and CEO of Walther Cancer Foundation, Indianapolis, IN

Hoosier Oncology Group, Inc.

Nasser Hanna, M.D., Chairman, Associate Professor of the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Vice-Chair, Principal Investigator for the Northern Indiana Cancer Research Consortium, South Bend, IN

James Ruckle, Ph.D., Secretary, President and CEO of Walther Cancer Foundation, Indianapolis, IN

Fuad Hammoudeh, Treasurer, Administrator of Cancer Programs at Clarian Health, Indianapolis, IN

Lawrence Einhorn, M.D., Chief Medical Officer, Distinguished Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Members At Large

Prasad Mantravadi, M.D., Principal Investigator for Radiation Oncology Associates, Evansville, IN

Patrick J. Loehrer, M.D., Interim Director and Medical Director at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Wael Harb, M.D., Principal Investigator of Horizon Oncology Center, Lafayette, IN

Naftali Bechar, M.D., Principal Investigator of Howard Regional Health Systems, Kokomo, IN

Clinical Trials Working Groups Co-Chairs

Breast

Kathy Miller, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Northern Indiana Cancer Research Consortium, South Bend, IN

Central Nervous System

Mark Henderson, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Charles Nock, M.D., University Hospital Case Medical Center, Cleveland, OH

Gastrointestinal

Gabi Chiorean, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Mary Mulcahy, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
Gynecology
Daniela Matei, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Greg Sutton, M.D., St. Vincent Oncology, Indianapolis, IN

Radiation
Achilles Fakiris, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Rao Prasad Mantravadi, M.D., Ft. Wayne Oncology & Hematology, Fort Wayne, IN

Genitourinary
Noah Hahn, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Guru Sonpavde, M.D., US Oncology, Texas

Hematology
Sheriff Farag, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Tamila Kindwall-Keller, M.D., University of Cleveland, OH

Head & Neck
Romnee Clark, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Daniel Weed, M.D., Clarian West Cancer Center, Indianapolis, IN

Supportive Care
Lawrence Einhorn, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Rudi Navari, M.D., University of Notre Dame, South Bend, IN

Thoracic
Nasser Hanna, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Jyoti Patel, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
IU Circle of Life

The Hoosier Oncology Group partnered with the IU Circle of Life Indiana University Mini Marathon & 5k Run/Walk.

Over 45 Hoosier Oncology Group Road HOG Champions participated in the event on Saturday, April 4, 2009, on the beautiful IU Bloomington campus. We raised over $10K for cancer research through the dedication and hard work of all Road HOG Champions.

“The Circle of Life, an Indiana University group responsible for planning the IU Mini Marathon, had the pleasure of partnering with Hoosier Oncology in 2009. (Hoosier Oncology Group’s) enthusiasm and energy was tangible. With its help, we were able to raise over $35k that will go towards a scholarship endowment for cancer survivors. It was a pleasure to work with the entire team, and our event was far more successful because of our partnership.”

—Matthew Berman
Immediate Past Co-President and Chief Financial Officer, IU Circle of Life Foundation
One of the most exciting areas in cancer research today is in the field of proteomics and bioinformatics to identify new biomarkers for cancer diagnosis, progression and to monitor therapies.

Dr. Buck and his colleagues in Discovery Park utilize Hoosier Oncology Group’s biorepository services for plasma proteomics studies.

“I am a cheerleader for the Hoosier Oncology Group because of the quality of the biospecimens and the information that accompanies these specimens. I know when I pull the samples out of my freezer, that these are high quality samples that are well-tracked, well-managed and information rich. Some researchers think biospecimens are too costly, but consistently high quality samples such as those collected by the Hoosier Oncology Group are invaluable.”

— Charles Buck, Ph.D.
Director of Operations, Bindley Bioscience Center in Discovery Park
Acknowledgements and Accolades

ASCO 2009

2009 follows the legacy of leadership, as Hoosier Oncology makes it 4 out of the last 5 years that our research outcomes have been featured as an oral presentation at the American Society of Clinical Oncology’s annual meeting.

Oral Presentation
A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU04-75.

Poster Presentation
Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06-116.

Publication
Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern: HOG GI05-92.
To the Board of Directors
Hoosier Oncology Group, Inc.
Indianapolis, Indiana

We have audited the accompanying statements of financial position of the Hoosier Oncology Group, Inc. (the “Organization”) as of June 30, 2009 and 2008 and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Organization’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Hoosier Oncology Group, Inc. as of June 30, 2009 and 2008, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Our audits were made for the purpose of forming an opinion on the basic financial statements taken as a whole. The schedules of functional expenses are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

Crowe Horwath LLP
Indianapolis, Indiana
January 29, 2010
Hoosier Oncology Group, Inc.
Statements of Financial Position
June 30, 2009

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalent</td>
<td>$2,777,917</td>
<td>$1,631,629</td>
</tr>
<tr>
<td>Accounts and grants receivable, net</td>
<td>915,276</td>
<td>1,015,850</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>–</td>
<td>2,217,251</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>65,548</td>
<td>74,513</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>69,181</td>
<td>140,841</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$3,827,922</strong></td>
<td><strong>$5,080,084</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES and NET ASSETS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$278,953</td>
<td>$341,365</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>117,562</td>
<td>621,531</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>42,364</td>
<td>39,818</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>225,388</td>
<td>285,118</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>664,267</strong></td>
<td><strong>1,287,832</strong></td>
</tr>
</tbody>
</table>

| Net assets                    |            |            |
| Unrestricted                  | 3,041,155  | 3,669,752  |
| Temporarily restricted        | 122,500    | 122,500    |
| **Total net assets**          | **3,163,655** | **3,792,252** |

| Total liabilities and net assets | **$3,827,922** | **$5,080,084** |
Hoosier Oncology Group, Inc.
Statements of Activities
June 30, 2009

<table>
<thead>
<tr>
<th>REVENUES</th>
<th>Temporarily Unrestricted</th>
<th>2009 Restricted</th>
<th>2008 Total</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>External support - research</td>
<td>$1,960,062</td>
<td>—</td>
<td>$1,960,062</td>
<td>$3,049,114</td>
</tr>
<tr>
<td>Federal research grants</td>
<td>406,683</td>
<td>—</td>
<td>406,683</td>
<td>97,317</td>
</tr>
<tr>
<td>Contributions and other grant support</td>
<td>80,587</td>
<td>—</td>
<td>80,587</td>
<td>4,011,356</td>
</tr>
<tr>
<td>Interest income</td>
<td>33,537</td>
<td>—</td>
<td>33,537</td>
<td>45,695</td>
</tr>
<tr>
<td>Other income</td>
<td>87,513</td>
<td>—</td>
<td>87,513</td>
<td>43,067</td>
</tr>
<tr>
<td>Total revenues</td>
<td>2,568,382</td>
<td>—</td>
<td>2,568,382</td>
<td>7,746,549</td>
</tr>
</tbody>
</table>

| EXPENSES                                       |                         |                 |            |            |
| Program services                               |                          |                 |            |            |
| Investigator initiated research                | 1,620,113                | —               | 1,620,113  | 1,358,357  |
| Industry research                             | 369,022                  | —               | 369,022    | 766,731    |
| Government research                           | 599,903                  | —               | 599,903    | 670,360    |
| Total program services                        | 2,589,038                | —               | 2,589,038  | 2,795,448  |
| Supporting services                            |                          |                 |            |            |
| Administration                                | 495,735                  | —               | 495,735    | 1,052,656  |
| Fundraising                                   | 112,206                  | —               | 112,206    | 106,193    |
| Total supporting services                     | 607,941                  | —               | 607,941    | 1,158,831  |
| Total expenses                                | 3,196,979                | —               | 3,196,979  | 3,954,297  |

| CHANGE IN NET ASSETS                           |                         |                 |            |            |
|                                              | (628,597)                | —               | (628,597)  | 3,792,252  |

Net assets, beginning of year                   | 3,669,752                | 122,500         | 3,792,252  | —          |

Net assets, end of year                         | $3,041,155               | $122,500        | $3,163,655 | $3,792,252 |
Hoosier Oncology Group, Inc.
Statement of Cashflow from Operating Activities
June 30, 2009

<table>
<thead>
<tr>
<th>CASH FLOWS FROM OPERATING ACTIVITIES</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td>$(628,597)</td>
<td>$3,792,252</td>
</tr>
<tr>
<td>Depreciation</td>
<td>71,660</td>
<td>76,072</td>
</tr>
<tr>
<td>Provision for bad debts</td>
<td>–</td>
<td>70,879</td>
</tr>
<tr>
<td>Contribution of HOG LLC assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>–</td>
<td>(1,496,161)</td>
</tr>
<tr>
<td>Fixed assets</td>
<td>–</td>
<td>(216,913)</td>
</tr>
<tr>
<td>Other assets</td>
<td>–</td>
<td>(55,353)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>–</td>
<td>1,151,131</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>–</td>
<td>558,561</td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>100,574</td>
<td>454,532</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>2,217,251</td>
<td>(2,217,251)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>8,965</td>
<td>(19,160)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(62,412)</td>
<td>(864,866)</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>(503,969)</td>
<td>621,531</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>2,546</td>
<td>39,818</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(59,730)</td>
<td>(273,443)</td>
</tr>
<tr>
<td>Net change in cash and cash equivalents</td>
<td>1,146,288</td>
<td>1,631,629</td>
</tr>
</tbody>
</table>

| SUPPLEMENTARY DISCLOSURE             |  |  |
| Contributions of assets, net of liabilities from Walther Cancer Foundation | – | $1,353,795 |
Thank You to Our Supporters

The Hoosier Oncology Group wishes to thank all those who contributed throughout the year to our mission of providing cutting-edge research to people within their community.

We are so fortunate to have many friends and supporters who give of their time, money, services, expertise and other valuable resources to help us fulfill our mission.

It is our hope that through their continued generosity, and through the generosity of others, that future generations may not know the pain of cancer.

Our Contributors*

**PLATINUM** ($5000 and above)
- Clarian Health
- Dr. Nasser Hanna
- Crowe Horwath LLP
- Horizon Oncology Center
- Michiana Hematology Oncology, PC
- Union Hospital

**SILVER** ($800 – $2499)
- Central Indiana Oncology Nursing Society
- Dr. Lawrence Einhorn
- Firestone Building Products
- Fuad Hammoudeh
- Heroes Foundation
- Dr. Patrick Loehrer, Sr.
- Dr. Mary Lou Mayer
- Ted Stansbury
- Dixie Weiss, In Memory of Jack Weiss

**GOLD** ($2500 – $4999)
- Ice Miller, LLC
- Oncology Hematology Associates of SW Indiana
- Quake Pletcher
- Paragon General Construction Company
- Southern Roofing – Tracey Day

**BRONZE** ($250 – $799)
- David Caldwell
- Kristin Fenech
- Kreg Gruber
- Kevin Harvey
- Dr. Kenneth Kesler
- Jeffery LeCount
- Dr. John McClean
- Anne Merkel
- Jennifer Nolan
- Phillip Pletcher
- Southern Roofing – Dave Tyndall
- Elizabeth Simpson
- Spring Creek Cattle Company
- Barbara Stansbury
- Duane Tyndall
FRIENDS ($249 and under)

Tarick Abdo  Karen Gallagher-Horning  Amanda Reed
Harold Anderson  Dan Gardner  Dan Rushing
Carol Anzalone  Susan Seggie  Don Russell
Joe Anzalone  Dr. Robert Goulet  Pat Russell
Janet Armstrong  Edward Gowens  Gregory Sandberg
Joanna Arnold  Louie Green  Sonal Sanghani
Suzanne Austin  Susan Haithcox  Ellen Saul
Al Baldwin  Andrea Hall  Stephanie Schoening
Troy Baughman  Jonathon Hardy  Bill & Wilma Schramm
Richard Bonebrake  Janet Harlan  Albert & Kevina Schumaker
Tom Borger  Lori Hedges  Ruth Ann Seaver
Carol Boyd  Brock Holst  Wilma Shafer
Kirk Bradley  Susan Hughes  Suzanne Short
Jan Broughton  Thelma Isgrigg  Brenda Sloan
Richard Burns  Jamar Johnson  Susan Stack
Donald Calvert  Timothy Judge  Cathi Steinacker
Stephen Calvert  Doug Keeslar  Teresa Swanson
Dr. Brian Clem  Jacqueline Kesler  Shad Tidler
Mary Cole  Paul Kilgore  Carol Tipton
Wade Cole  Pam Krengel  Jan Towner
Jeffrey Congdon  Cordelia Lewis  Thomas Ulbright
Julie Cooper  Stacey Loge  Kathleen Vareira
Rich Correll  Jenny Lui  William Voelz
Annette Delaney  Charles Margolis  John Waffle
Cindy DeLeon-Ewing  Trina Martinez  Scott Waffle
Edwin Dermond  Lisa Meriweather  Thomas & Joann Walker
Judy DiAgostino  Mark Merryman  Cidney Walter
Douglas Dobson  Dr. David Moore  Jerry Walters
Leslie Donnelly  Karla Morton  James Weaver
Tim Dugle  Cheryl Motosicky  Peggy Weber
Suzanne Eger  Dr. Harikrishna Nakshatri  Earita Webster
Jan Elrod  National Bank of Indianapolis  Dana Weiss
Matt Eppers  Tracey Odenwelder  Scott Welch
Leah Essex  Kelly O’Donnell  Gayla Williams
Dr. William Fisher  Stephen Parker  Ruth Workman
Michael Fisher  Susie Peebles  Betsy Yonker
Bill Flora  Shawna Ping
George Furman  Jason Plassard
David Gaglione  Antony Predan

The Hoosier Oncology Group also wishes to thank all the dedicated investigators, clinical research site personnel and, most importantly, the patients who make our research possible.

*The Hoosier Oncology Group strives to acknowledge each and every contributor accurately. The information above reflects contributions made between July 1, 2008—June 30, 2009. If the information listed above is incorrect or not inclusive, please contact our offices at 317-921-2050 and ask for Cyndi Burkhardt. Thank you for your support!
Our Community Reach is Far and Wide

Our partnerships with the many academic and community cancer clinics across the United States enables oncologists to participate in meaningful cancer research while providing cutting-edge treatment to patients in their own communities.

ARKANSAS
Highlands Oncology Group, Fayetteville

DELWARE
Helen F. Graham Cancer Center, Newark

FLORIDA
Shalk Cancer Center, University of Florida, Gainesville

ILLINOIS
Ingalls Memorial Hospital, Harvey
Karloogg Cancer Care Center, Northshore Univ. Health System, Evanston
Medical & Surgical Specialists, LLC, Galesburg
Northwestern University Feinberg School of Medicine, Chicago
Rush-Presbyterian, Chicago
The University of Chicago, Chicago

INDIANA
Arnett Cancer Care, Lafayette
Cancer Care Center of S Indiana, Bloomington
Cancer Care Center, Inc., New Albany
Central Indiana Cancer Centers, Indianapolis
Community Cancer Care, Indianapolis
Community Regional Cancer Center, Indianapolis
Evansville Multi-Specialty Clinic, Evansville
Ft. Wayne Medical Oncology & Hem, Ft. Wayne
Good Samaritan Hospital, Vincennes
Center for Cancer Care at Goshen Health System, Goshen
Horizon Oncology Center, Lafayette
IN Onc/Hem Consultants, Indianapolis
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Medical Center of Vincennes, Vincennes
Medical Consultants, P.C., Muncie
Medical Oncology/Hematology, Indianapolis
Monroe Medical Associates, Munster
Northern Indiana Cancer Research Consortium, South Bend
Oncology Hematology Associates of SW Indiana, Newburgh
Providence Medical Group, Terre Haute
South Bend Clinic, South Bend
St. Vincent Gynecologic Oncology, Indianapolis

LOUISIANA
Louisiana State University Health System, Leonard J. Chabert Medical Center, Houma

MARYLAND
The Sidney Kimmel Cancer Center, John Hopkins, Baltimore
University of Maryland, Baltimore

MASSACHUSETTS
Dana Farber Cancer Institute, Boston

MISSOURI
Washington University School of Medicine, St. Louis

NEBRASKA
Methodist Cancer Center, Omaha
University of Nebraska Medical Center, Omaha

NEW JERSEY
(Fox Chase), Freehold
(Fox Chase), Hamilton
(Fox Chase), Howell
(Fox Chase), Lakewood
(Fox Chase), Manahawkin
(Fox Chase), Marmora
(Fox Chase), Mickleton
(Fox Chase), Mount Holly
(Fox Chase), Princeton
(Fox Chase), Redbank
(Fox Chase), Trenton
(Fox Chase), Vineland
(Fox Chase), Voorhees
Girish Amin (Fox Chase), Brick
Hem Onc Associates S.J., P.A., Mt. Holly
Myron Bednar (Fox Chase), Flemington
NEW YORK
Schwartz Gynecologic Oncology, PLLC, Brightwaters

OHIO
University Hospitals of Cleveland, Ireland Cancer Center, Cleveland

OREGON
Oregon Health and Science University, Portland
Providence Portland Medical Center, Portland

PENNSYLVANIA
(Fox Chase), Danville
(Fox Chase), Drexel Hill
(Fox Chase), Harrisburg
(Fox Chase), Langhome
(Fox Chase), Paoli
(Fox Chase), Philadelphia
(Fox Chase), Pottstown
(Fox Chase), West Grove
(Fox Chase), West Reading
Consultants in Medical Oncology & Hematology, Drexel Hill
Corey Langer (Fox Chase), Philadelphia
Pennsylvania Oncology Hematology Associates, Philadelphia
Tony Magdalinski (Fox Chase), Sellersville
University of Pennsylvania, Philadelphia

SOUTH CAROLINA
Medical University of South Carolina, Charleston
Medical University of South Carolina, Spartanburg

TENNESSEE
The West Clinic (ACORN), Memphis

TEXAS
Baylor College of Medicine – Methodist Breast Center, Houston
CTRC at the UT Health Science Center at San Antonio
The Methodist Hospital, Houston
Texas Oncology Cancer Center, Austin
US Oncology, Houston
University of Texas Southwestern Medical Center, Dallas

VIRGINIA
Virginia Oncology Associates, Newport News

PERU
Instituto de Enfermedades Neoplasticas (INEN), Lima

POLAND
Medical University of Gdansk (Poland), Gdansk

UNITED KINGDOM
St. Barts and The London School, London